OBJECTIVE: To assess the efficacy and @entity137 of the combination of @entity1311 plus @entity3003 as neoadjuvant chemotherapy (NACT) for locally advanced @entity5 (LACC) prior to radical hysterectomy and pelvic lymphadenectomy. METHODS: We reviewed @entity1 with @entity5 of the International Federation of Gynecology and Obstetrics (FIGO) stage @entity3847 -IIB who underwent neoadjuvant chemotherapy (NACT) with @entity1311 plus @entity3003 followed by radical hysterectomy (NACT group) or only received primary radical surgery (PRS group) in our hospital between Jan 2007 and Jan 2012. @entity137 , NACT response, surgery pathological factors and survival data were collected and analyzed. RESULTS: In the NACT group, the overall response rate was 71.3% (82/115). Eighteen (15.7%) @entity1 achieved complete remission. Well differentiated @entity5 showed a more favorable response to NACT (P=0.011). Myelosuppression was the most common adverse effect (51.7%) and serious adverse effects were rare (3.4%). The median follow-up period was 44 months (range, 6-75). The NACT responders had significantly longer OS and PFS when compared to the non-NACT responders and @entity1 in the PRS group. CONCLUSION: @entity1 with LACC can benefit from neoadjuvant chemotherapy with @entity1311 plus @entity3003 when they have response to the chemotherapeutic agents.

Clinical efficacy and safety of XXXX plus @entity3003 as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for Stage @entity3847 -IIB @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cervical cancer', 'tumors'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity3847 :: ('23542', 'Gene') :: ['IB2']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
